Kineta (KANT) AI Stock Analysis

• Market Cap: $4.55M
• Dividend Yield: N/A
• Average Volume (3M): 18.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.43
• Shares Outstanding: 51,099,000
• 10 Day Avg. Volume: 6,928
• 30 Day Avg. Volume: 18,681
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ―

Kineta faces financial challenges and lacks profitability, reflected in a low financial performance score. Technical analysis shows no strong trends, and valuation metrics are unappealing due to negative earnings. The recent merger announcement offers a positive outlook, but overall risks weigh heavily.

Kineta Business Overview & Revenue Model

Company Description

Kineta, Inc. (KANT) is a clinical-stage biotechnology company focused on developing novel therapies in the immuno-oncology sector. The company's core products include innovative treatments aimed at enhancing the immune system's ability to combat cancer. Utilizing advanced immunotherapeutic approaches, Kineta seeks to address critical unmet needs in oncology, offering potential breakthroughs in cancer treatment.

How the Company Makes Money

Kineta makes money primarily through partnerships, collaborations, and licensing agreements with larger pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of their therapies. Additionally, Kineta may receive funding from grants and government programs aimed at supporting innovative cancer research. The company’s revenue model heavily relies on the success of their clinical trials and the market acceptance of their therapies once approved.

Kineta Financial Statement Overview

Summary

Kineta's financial health shows improvements in revenue and narrowing losses, yet persistent challenges in profitability and cash flow generation. The balance sheet reflects a declining equity position, raising concerns about long-term financial stability.

Income Statement

The company has shown improvement in its net income and revenue figures, with a significant reduction in losses from 2022 to 2023. However, the overall profitability remains negative across several metrics such as EBIT and EBITDA margins. Revenue growth is noteworthy from 2022 to 2023, but gross profit margins are low, indicating challenges in controlling costs.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio as of 2023, highlighting a manageable leverage position. However, the company has shown declining equity levels over time, which poses sustainability concerns. The equity ratio indicates a low level of equity financing, which could be a risk factor during financial distress.

Cash Flow

Cash flow analysis reveals negative operating cash flow and free cash flow, indicating potential liquidity issues. The free cash flow growth is negative, emphasizing challenges in generating sufficient cash from operations. The operating cash flow to net income ratio is weak, which suggests inefficiencies in converting income into cash.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	―	―	―	―	―
Gross Profit	5.44M	1.95M	9.09M	6.90M	5.00M
EBITDA	-15.73M	-59.64M	-10.45M	-1.99M	-29.26M
Net Income	-14.10M	-63.41M	-11.82M	-8.05M	-31.21M
Balance Sheet
Total Assets	10.28M	17.43M	13.35M	114.83M	17.61M
Cash, Cash Equivalents and Short-Term Investments	―	―	―	―	―
Total Debt	1.32M	2.26M	21.69M	35.29M	15.22M
Total Liabilities	7.22M	12.87M	25.30M	58.63M	109.51M
Stockholders Equity	―	―	―	―	―
Cash Flow
Free Cash Flow	-15.88M	75.00K	-17.85M	-18.17M	-27.85M
Operating Cash Flow	-16.21M	75.00K	-17.85M	-17.94M	-27.21M
Investing Cash Flow	―	―	―	―	―
Financing Cash Flow	―	―	―	―	―

Kineta Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KANT, the sentiment is Positive. The current price of 0.34 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.28, and below the 200-day MA of 0.43, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 62.70 is Neutral, neither overbought nor oversold. The STOCH value of 102.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KANT.

Kineta Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.60B	0.11	-62.95%	2.07%	16.16%	0.31%
KURA	47 Neutral	$560.14M	―	-41.84%	―	―	3.95%
EPIX	46 Neutral	$83.01M	―	-23.07%	―	―	-19.93%
KANT	43 Neutral	$4.55M	―	-460.90%	―	―	―
BCLI	40 Underperform	$6.79M	―	234.90%	―	―	62.35%
CYCC	38 Underperform	$27.16M	―	-1949.77%	―	-89.76%	80.28%
BIVI	38 Underperform	$14.04M	―	-93.23%	―	―	66.72%
GRTX	22 Underperform	$1.78M	―	13.71%	―	―	75.56%

Kineta Corporate Events

Kineta Merges with TuHURA to Enhance Cancer Treatment

Kineta, Inc. has entered into a merger agreement with TuHURA Biosciences, Inc., where TuHURA will acquire Kineta, including rights to its novel KVA12123 antibody. This merger is expected to enhance TuHURA’s pipeline with Kineta’s Phase 2 checkpoint inhibitor and create synergies with TuHURA’s existing technologies, potentially improving treatment outcomes for blood-related cancers. The transaction, subject to customary closing conditions, is anticipated to close in the first quarter of 2025.

More about Kineta

Kineta, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for oncology, specifically addressing cancer immune resistance. TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing technologies to overcome cancer immunotherapy resistance.

YTD Price Performance: -83.75%

Average Trading Volume: 51,482

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $7.24M

Kineta and TuHURA Enter Acquisition Agreement

Kineta, Inc. and TuHURA Biosciences have entered into a non-binding letter of intent for a potential transaction where TuHURA would acquire rights to Kineta’s VISTA blocking antibody, KVA12123. This potential acquisition aligns with TuHURA’s strategy of expanding its immune-oncology pipeline, which includes novel therapies like IFx-2.0 and IFx-3.0 targeting various cancers. TuHURA aims to achieve several milestones in 2024 and 2025, including initiating Phase 3 trials and completing the acquisition, enhancing its position in the biotechnology sector.